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Abstract
Background. Secondary prevention medications reduce risk of stroke recurrence, yet many people 
do not receive recommended treatment, nor take medications optimally.
Objective. Exploring how patients report making use of practitioners’ advice on secondary 
prevention medicines on an online forum and what feedback was received from other 
participants.
Methods.Thematic analysis of the archive of Talkstroke (2004–2011), UK. Posts including any 
secondary prevention medication terms, General Practitioner (GP) and their replies were 
identified.
Results. Fifity participants talked about practitioners’ advice on secondary prevention 
medications in 43 discussion threads. Patients consulted practitioners for reassurance and 
dealing with side effects. Practitioners’ advice varied from altering to maintaining current 
treatment. Three main themes emerged from the use of practitioners’ advice: patients following 
advice (reassured, happy when side effects made tolerable, or still retaining anxiety about 
treatment); patients not following advice (admitting adherence on-off or stopping medications 
as side effects still not tolerable); asking other participants for feedback on advice received. 
Practitioners’ advice was disregarded mainly when related to dealing with statin side effects, 
after one or two consultations. Themes for feedback involved sharing experience, directing back 
to practitioners, or to external evidence.
Conclusions. Side effects of secondary prevention medications and statins in particular, cause 
anxiety and resentment in some patients, and their concerns are not always addressed by 
practitioners. Practitioners could consider more proactive strategies to manage such side effects. 
Forum feedback was appropriate and supportive of the practitioners’ advice received. Our findings 
from peer-to-peer online conversations confirm and widen previous research.
Key words:  General Practitioners, internet, medication adherence, primary health care, stroke, secondary prevention.
Introduction
Three in 10 stroke survivors will go on to have a recurrent stroke 
or TIA, which are potentially preventable (1). The estimated cost of 
stroke care in UK is about £9 billion a year (1,2). The use of anti-
hypertensives, lipid lowering agents and anticoagulants/antiplatelets 
may reduce the risk of stroke by about 75% (3). However, persis-
tence with secondary prevention medications decreases over time, in 
particular for statins and anticoagulants/antiplatelets (4). Data from 
the Netherlands revealed that by 1 year after stroke, 22% of stroke 
survivors who had been taking oral anticoagulation had stopped, 
half of whom did so ‘for non-medical reasons’ (5).
Additionally, suboptimal adherence in stroke survivors still on 
secondary prevention medications treatment also leads to inad-
equate risk factor control (6,7). Patients’ perceptions of their medi-
cines influence medicine-taking behaviour: absence of concerns 
about medications, knowledge of side effects, clear understanding 
of the consequences of non-adherence and a good routine of taking 
medications have been identified as factors associated with better 
adherence after stroke (8–10).
Primary care practitioners play a pivotal role in managing sec-
ondary prevention medications in stroke survivors. Although the 
quality of prescribing in the secondary prevention of stroke is 
reported to be good (11,12) evidence shows that many of the dif-
ficulties stroke survivors have adhering to secondary prevention 
strategies are potentially preventable with tailored information, 
monitoring and follow-up by primary healthcare professionals (13). 
Appropriate interaction between patient and health professional is 
recognized as becoming an increasingly important factor (14) and its 
quality correlating with the success of self-management, adherence, 
satisfaction and health outcomes (15,16).
Online fora allow social interactions, through which participants 
can join in the discussions at their own convenience. Stroke survivors 
of both sexes, across a wide age range and disability degrees accessed 
the online forum of the Stroke Association (17). There is evidence 
that inappropriate medical information or health behaviours can be 
identified and corrected by peers in stroke (17) and cancer fora (18).
The aim of this study was to identify whether practitioners’ 
advice on secondary prevention medications was discussed within 
the forum and analyse how stroke survivors and their carers used 
such advice, to inform interactions between patients and primary 
care health professionals in the context of secondary prevention 
medications.
Methods
Design
We conducted a qualitative analysis of stroke survivors’ posts on a 
moderated UK web forum. We included posts about practitioners’ 
advice on secondary prevention medications written by stroke survi-
vors and by people posting about stroke survivors.
Setting
The analysis was performed on the archives from TalkStroke, a 
UK based online forum hosted by the Stroke Association web-
site, with 21 596 posts written between 2004 and 2011 by 2,348 
participants (17).
Ethics
The Stroke Association transferred the archives to ADS with permis-
sion to use the data for research purposes. More extensive details 
about the ethics of performing research on this online forum are 
reported elsewhere (17). To protect the identity and intellectual 
property of forum participants, we chose not to use quotes, despite 
this being normal practice in qualitative research. Instead, we used 
descriptions of quotes throughout the text. We did not apply our 
own interpretation to these descriptions, but aimed to summarise 
what was being said.
Identification of study participants
A word list of unique terms of the archive file of Talkstroke was 
generated using AntConc3.2.4 (19), an online free corpus analy-
sis toolkit for text analysis. Terms related to secondary prevention 
medications were selected (e.g. Amlodipine, statin, warfarin), includ-
ing misspellings (e.g. Asprin, simvastin), brand names (e.g. Lipitor, 
Plavix) and drug categories (e.g. statin, diuretics etc.). Posts includ-
ing both secondary prevention medications terms and [i.e. General 
Practitioner ‘GP’] were identified (see Figure  1). Participants were 
identified by the usernames linked to selected posts. Characteristics 
of stroke survivors including demographics and information of 
Figure 1. Flowchart illustrating the analysis.
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stroke type (see Table 1) were retrieved from the usernames taking 
advantage of data from a previous study (17).
The threads of discussions for each selected post were analysed 
in details. Posts located chronologically before or after the selected 
posts were added to the analysis, provided they were discussing the 
use of practitioners’ advice on secondary prevention medications. 
These extra posts did not necessarily include the word ‘GP’ and sec-
ondary prevention medications terms.
Analysis
Posts were analysed using thematic analysis using an inductive or bottom 
up approach (20,21). An initial coding framework was developed, which 
was adjusted as new data were added. Coding was performed indepen-
dently by Nkeonye J Izuka and Anna De Simoni. Analysis was discussed 
until agreement was reached and the coding framework finalised.
The feedback received by the forum was performed by Matthew 
A W Alexander and ADS. Posts were defined as ‘false’ when includ-
ing factually incorrect statements and ‘misleading’ when likely lead-
ing a medically naive reader to a false factual conclusion, according 
to what reported by Esquivel et al in a study on online peer support 
group for cancer (18).
Cytoscape software (22) (an open source software platform for 
visualizing complex system analysis) was used to create the associa-
tion graph grouping the emerging themes (Figures 2 and 3).
Results
The archives contained 1416 posts naming secondary prevention 
medication terms (see Figure  1). Posts selected were part of 43 
different discussion threads. Analysis of threads brought additional 
11 posts to the analysis, up to a total of 69 posts: 14 posts ini-
tiating the conversation about the use of practitioners’ advice on 
secondary prevention medications, 42 responses to initiating posts, 
13 returning posts written by the same participants who started the 
conversation.
Participants
A total number of 50 participants posted about use of practition-
ers’ advice on secondary prevention medications, 33 stroke survivors 
and 17 carers (see Table 1). There were 27 females, 21 males and 2 
participants whose sex was not stated. The median age of partici-
pants was 49 years. The average period since stroke was 2.3 years, 
while the median 0 years, indicating that at least half of participants 
took part in the forum within a year since suffering from stroke.
Themes
Initial coding revealed four over-reaching categories, under which 
themes were grouped: (i) patients’ main issues for asking practition-
ers’ advice, (ii) practitioners’ advice received on secondary preven-
tion medications, (iii) patients’ use of practitioners’ advice and (iv) 
feedback received by other forum participants.
The thematic analysis is summarised in Figures 2 and 3.
Patients’ main issues for asking practitioners’ advice
Patients’ reasons for consulting their practitioners fell into two main 
categories (see Figure 2 and 3).
1) Being on correct treatment. Patients consulted their practitioner 
to reassure themselves they were on the correct secondary pre-
vention medications.
A woman had lost use of her right arm, leg and speech. She was 
commenced on warfarin for life due to her atrial fibrillation. Her 
GP had reassured her that as long as she was on warfarin, the risk 
of getting another stroke was low. (Female, age and age of stroke not 
stated, N13).
2) Dealing with side effects.
A woman asked her GP if she could stop taking the statins due to 
the horrible head pain that was supposed to only last short term but 
seemed to continue every day. (Female, current age and age at stroke 
not stated, N3).
Practitioners’ advice on secondary prevention 
medications
Four main themes emerged on the type of practitioners’ advice 
reported by forum participants (see Figures 2 and 3).
1) Changes to medications: starting/stopping or modifying second-
ary prevention medications.
A man was on antihypertensives, anticoagulants and simvastatin 
simultaneously. He developed painful muscular spasms/cramps and 
his GP decided to try discontinuing the simvastatin to see whether 
responsible for his symptoms. (Male, present age and age at stroke 
not stated, N8).
A woman described her GP placing her on atorvastatin 10 mg 
and increasing it slowly to avoid side effects. She was tolerating this 
well. (Female, age and age at stroke 54 years, N22).
2) No change in treatment.
Table 1. Characteristics of study participants
Dataset
Archives of the Talkstroke forum 2004 to 2011, 
2348 participants, UK
Sample characteristics
N Median (range)
Total number of participants in this study 50
Age at stroke 37 49 years (17–88)
Participants’ posts
 Number of posts on the forum/participant 16 (1–4932)
  Number of posts about use of practitioners’ 
advice on secondary prevention  
medications/participant
1 (1–13)
Identity person posting
 Stroke survivor 33
 Carer 17
Gender of stroke survivor
 Male 21
 Female 27
 Not stated 2
Type of stroke
 Ischemic 6
 Haemorrhagic 4
 Stroke (unspecified) 35
 TIA 5
Secondary prevention medication classa No of posts
 Antihypertensives 17
 Statins 33
 Antiplatelets/anticoagulation 37
aEach post may include discussion about one or more medication classes.
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A man wrote about recently having more leg and foot pain plus 
tremor on his left hand when typing, sleeping badly as well and neck 
pain on right side. He said he had to work as he had his own com-
pany and his partner needed his help. He was on aspirin, statin and 
ramipril. He had spoken to his GP about whether the drugs were the 
cause of his symptoms. He requested an X-ray of his neck and said 
that he needed to keep taking the drugs to avoid stroke recurrences 
and consequent worsening of his quality of life. (Male, 59 years, age 
at stroke 56 years, N27).
3) Advice about medications in special situations, like flights, dental 
procedures or starting an additional treatment (e.g. a painkiller).
A woman said recently she had to have all her teeth out, and her 
dentist wanted her to stop the aspirin. She contacted her GP about 
it. (Female, 54 years, age at stroke 46 years, N6).
Patients’ use of practitioners’ advice
Three main themes were identified for patients’ use of practition-
ers’ advice (see Figures 2 and 3): followed, not followed, and ask-
ing forum participants. These posts were analysed irrespective of 
whether they were initiating posts, replies or returning posts written 
by the same participants who started the conversation.
1) Followed
a. Patients simply stating that they were following their practition-
ers’ advice
A woman said her GP advised her not to stop the aspirin for a dental 
procedure, and if she was bleeding the dentist would have had to 
cope. She welcomed and followed this advice. (Female, 54 years, age 
at stroke 46 years, N6).
b. Patients feeling reassured by their practitioners’ advice
A woman was replying to a forum participant who was enquiring 
about potential treatment for stroke-related pains. She described get-
ting a new pain relief medication from her GP in form of a “patch” 
that dispenses opiate-based pain relief over the course of a week, 
similar to nicotine patches. She reported that her GP said there were 
no contra-indications with being on all other medications she was 
taking for blood pressure, cholesterol and anti-coagulants. (Female, 
54 years, age at stroke 46 years, N6).
c. Patients following the practitioners’ advice provided secondary 
prevention medications side effects were made tolerable
A woman described her boyfriend who had a stroke suffering erectile 
dysfunction and was replying to another participant who also com-
plained about the same problem following stroke. Her boyfriend was 
on atenolol. His GP attributed the symptom to atenolol and advised a 
gradual reduction of the tablet dose and eventually stopped it, swapping 
it to Ramipril and Amlodipine. The boyfriend followed the advice and 
his symptoms resolved. (Male, 51 years, age at stroke 49 years, N1).
d. Patients remaining anxious about secondary prevention medica-
tion after practitioners’ advice
A woman said that although her GP had reassured her that being on 
warfarin reduces her risk of further stroke and she believed this and 
was taking the drug, she still kept worrying. (Female, age and age of 
stroke not stated, N13).
A woman talked about her husband being on several antihy-
pertensives following his stroke. He was suffering from erectile 
dysfunction but his GP said he could not alter or discontinue 
any drug until he had heard back from the consultant. The cou-
ple agreed to wait although they were wishing the GP had done 
Figure 3. Thematic analysis about GP advice on cholesterol lowering medications. In horizontal, themes emerging according to: patients’ main issues for 
asking practitioners’ advice (dark grey background), practitioners’ advice received on secondary prevention medications (white background) and patients’ use 
of practitioners’ advice (light grey background). 
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something to ‘speed things up’ and make sure that the consultant 
who was writing the report was actually taking into account the 
side effect of erectile dysfunction. (Male, age and age at stroke not 
stated, N38).
e. Patients feeling humbled by the advice received
A woman asked her GP if she could stop taking the statins due to 
the horrible head pain that was supposed to only last short term but 
seemed to continue every day. Her GP put her head in her hands and 
said that she has had a warning and she could not tell her not to take 
them. The patient felt very humbled and like a 5 year old (Female, 
current age and age at stroke not stated, N3).
2) Not followed
a. Side effects not tolerable, participants’adherence on-off.
A man described he was 11 months post stroke and just had a cho-
lesterol test with figure at 4.1. His GP wanted to increase his ator-
vastatin dose to 80 mg from 40 but he was already suffering what 
he believed were side effects: muscle pain, weakness and generally 
feeling ill and if he left the statin off for a few days, felt a bit better. 
He was asking whether anyone could suggest a better statin or have 
an opinion. (Male, 59 years, age at stroke 56, N27).
b. Side effects not tolerable, participant admitting stopping the 
medication.
A woman said that she has tried to get her husband’s statins reduced, 
but his GP insisted on giving him 40 mg even though his cholesterol 
level was only 5.6. 40 mg was making him chronically tired so he just 
stopped taking them. (Male, 54 years, age at stroke 52 years, N32).
A woman complained suffering from bouts of light-headedness, 
brain fog, tight feeling across her chest, tingling and pins and needles 
all over. She stopped taking the Simvastatin and subsequently her 
GP swapped her to Atorvastatin. However, after taking it for about 
a week the tingling started again together with a full sensation to her 
head and neck with a very ‘foggy’ brain, and tight chest. She declared 
that at that point she stopped herself taking the Atorvastatin, con-
vinced that statins were having adverse effect on her. There was no 
mention of her GP being informed. (Female, 52 years, 52 years at 
stroke, N35).
c. Checking themselves for practitioners’ prescribing mistakes
A man was suggesting to another forum participant to try getting a 
book called British National Formulary, which he could often find 
in second hand shops as new books were published every year. He 
explained that the BNF was the guide that the medical professionals 
use to prescribe medicines, what every drug is for and what dosages 
are safe. He reported he had caught his GP prescribing the wrong 
(dangerous) dose of blood pressure pills to his Father-in-law. He con-
cluded that patients should ‘keep an eye on them’. (Male, age and age 
at stroke not stated, N 19).
3) Asking forum participants
A woman talked about her 88-year-old mother who had a brain 
bleed. She was on tramadol, gabapentin and simvastatin, and now 
out of hospital. She said that while her mother was in hospital the 
pharmacist would look at the combinations of drugs daily, and see 
whether some drugs could be taken down a dose, or up as thought 
necessary. Because her mother was also on spironolactone and furo-
semide, she discussed her mother’s medication with her GP, though 
it all seemed a bit hit and miss. The GP said she could drop down 
a 20 mg on this or that, it seemed down to her to decide, as the 
pill dispenser. She was also lately suffering from tummy upsets, so 
she has been trying through trial and error to take out for example 
simvastatin, as she was on soya milk to reduce cholesterol anyway, 
to determine if that was the drug causing the symptom. The mother 
was also on iron tablets. She did ask for a GP review, but was not 
getting far with that, and most of the side effects on the drug leaflets 
seemed to indicate diarrhoea. She concluded by saying she was try-
ing to eradicate the suspect drugs and asking forum participants for 
advice. (Female, 89 years, age at stroke 88 years, N2).
Feedback received by other forum participants
42/69 posts were feedback received by forum participants and 
revolved around four main themes (see Table 2):
1) Sharing own experience of secondary prevention medications/
practitioners’ advice on secondary prevention medications.
A woman replied to a participant hoping the symptoms described 
were just a one-off like many patients seem to have after a stroke. 
She empathised that it was frustrating feeling almost back to normal 
and then suddenly ‘feeling rubbish’ again. This was the pattern for 
herself and she had checked with GP whether this could be down 
to her medications. (Female, age and age at stroke not stated, N13).
2) Sharing own knowledge
A woman replied to a participant who was asking which drugs her 
mother might be able to stop taking. She explained that statins are 
taken because the liver produces cholesterol naturally and diet alone 
will not be as effective. (Female, 54 years, age at stroke 46 years, N6.)
3) Directing to practitioners, often with expectations of practition-
ers’ actions (e.g. practitioner to check whether side effects could 
be related to medications).
A woman replied to another participant suggesting to discuss symp-
toms together with all current medications with the GP. (Female, age 
and age at stroke not stated, N13).
4) Directing to external source of information (scientific or other-
wise).
A man suggested to a participant to look up a recent article on the 
British Broadcasting Corporation website discussing the role of cho-
lesterol in stroke (Male, age and age at stroke not stated, N46). 
Table 2. Themes emerging from the feedback received by forum participants, according to secondary prevention medications category
No. posts Sharing own  
experience
Sharing own  
knowledge
Directing to  
practitioners
Directing to external 
resources
Total 42 34 11 15 2
Antihypertensives 10 9 3 5 1
Antiplatelets/anticoagulant 13 10 1 8 0
Cholesterol lowering 27 22 10 6 2
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Because most statements were based on personal experience or 
own knowledge rather than factual information, no false or mis-
leading statements were identified, according to the definition by 
Esquivel et al. (18).
Replies to posts, including the ones about not following prac-
titioners’ advice, rather consisted in sharing their own experience 
of secondary prevention medications, own knowledge on secondary 
prevention medications and directing participants back to healthcare 
professionals or external source of information. Posts that did not 
receive any feedback were focussed on other issues than secondary 
prevention medications, with practitioners’ advice on secondary pre-
vention medications mentioned only incidentally.
Statins received the most complex feedback (see Table 2, Figure 2 
and 3).
Two ‘super users’ contributed to 36% of feedback posts (a man 
and a woman, who wrote a total of 4932 and 978 forum posts, 
respectively). Their advice revealed appropriate understanding of 
secondary prevention medications and a good rapport with their 
practitioners.
Discussion
Summary
The online forum was a source of information on the use of prac-
titioners’ advice on secondary prevention medications and shed 
light on the role of peer-to-peer conversations in checking experi-
ences and advice received from professionals. These data suggest 
that side effects of secondary prevention medications, and statins 
in particular, cause anxiety and resentment in some patients, and 
their concerns are not always addressed by practitioners. Patients 
admitted suboptimal adherence or stopping taking statins after 1 or 
2 practitioners’ consultations. Educating patients in advance about 
side effects and the potential need of several attempts to find suit-
able treatment, in addition to offering a follow-up after medication 
changes might be considered, in particular for statins. Follow-up 
might also be helpful when the advice consists in persisting with sec-
ondary prevention medications despite side effects. Forum feedback 
was appropriate and supportive of the practitioners’ advice received. 
No false or misleading secondary prevention medications posts were 
identified in this study context.
Strengths and limitations
This is the first study that used online forum data to explore how 
patients use practitioners’ advice on secondary prevention medica-
tions after stroke. A  strength of this work lies in the self-initiated 
nature of the data provided by online fora and the possibility to ana-
lyse patients’ perspectives at the time they actually were experiencing 
issues with secondary prevention medications and asking/receiving 
practitioners’ advice. Such data are less likely to be affected by self-
presentation, reactivity and recollection biases and by the influence 
of the researcher’s agenda (23). Moreover fora allow collection 
of data from participants who might not take part in traditional 
research studies and from a wide geographical location. A main limi-
tation of this approach is the inability to ask follow-up questions to 
participants. Information about participants such as age at stroke 
and sex was limited to what was revealed within their posts. Forum 
participants were younger compared with most patients with stroke, 
therefore the views on practitioners’ advice on secondary preven-
tion medications by older patients might be under-represented. Some 
users might have use the word ‘doctor’ to refer to their practitioners, 
while our search was limited to posts including the word ‘GP’, there-
fore might have missed some relevant conversations. Forum data 
originated either from a population of stroke survivors who were 
‘computer-literate-online-forum-users’ (a selected population of 
stroke survivors) or from family members of patients with stroke 
(representing more widely the population of stroke survivors who 
might not be computer literate. Sixty percent of all Talkstroke users 
were family members rather than patients with stroke) (17). While 
we could analyse the feedback of forum participants, we could not 
analyse how patients with stroke and their carers reading but not 
taking part in the forum were affected. There can be up to 26:1 
readers per author of a forum message (24) and forum posts can be 
retrieved and read from looking up keywords in search engines like 
Google, without the need of registering or accessing the forum itself.
The posts analysed dated between 2004 and 2011, secondary 
prevention medications practice and medications themselves have 
changed over the years, and the practitioners’ advice received by par-
ticipants may not reflect current practice. We were not able to assess 
the change in patients’ use of secondary prevention medications or 
practitioners’ advice over the 7 years span, as the date of posts was 
not available to us. The forum was moderated and some of the posts 
might have been removed or affected by the moderation process.
Comparison with existing literature
Previous studies have shown a decline in uptake of secondary pre-
vention medications after stroke, with higher rate of discontinua-
tion of statins compared to other secondary prevention medications 
(4–7). Younger age and concern about medication have been associ-
ated with non-adherence (9,25), in agreement with our results. When 
practitioners’ advice was sought about side effects, patients appre-
ciated practitioners’ attempts to address the issues, provided side 
effects were resolved or made tolerable. When side effects were still 
not tolerable and active measures were not taken by the practitioner 
dissatisfaction was evident. This is in keeping with a previous study 
that showed that inadequate consideration of patients’ informa-
tion needs, engagement with healthcare professional and follow-up 
and monitoring were barriers to adherence to secondary prevention 
medications (13). Indeed a systematic review of trial interventions 
including a component to address adherence to antihypertensives 
after stroke are associated with improved blood pressure control 
(26). Interestingly patients who decided to stop taking statins did 
so after only one or two consultations, giving the impression they 
felt that the number of options for adjusting treatment was limited. 
Most patients who were not satisfied with their practitioners’ advice 
turned to other forum participants to receive information and sup-
port. This strategy seemed successful, considering the number of 
patients who wrote back thanking for the feedback received, as 
previously shown (17). Research on online networks suggests that 
forum members with high number of connections with other partici-
pants play an important part in the success of online fora (27). The 
‘super users’ identified in this study provided a significant proportion 
of the feedback to other participants, in keeping with these findings. 
The good rapport of these super-users with their practitioners and 
their appropriate knowledge about secondary prevention medica-
tions played an important role in the ability of the forum to iden-
tify and provide feedback on inappropriate information and health 
behaviours in the context of secondary prevention medications.
Unaddressed fear of stroke recurrence emerged from this study, 
in keeping with previous reports (28).
Data about practitioners’ advice on dealing with non-
intentional non-adherence factors like forgetting or poor tablet 
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routines were not retrieved within our data, despite this being 
a recognised important factor affecting overall adherence after 
stroke (8).
Implications for research and practice
This study offers interesting insight into shared decision-making in 
patient-centred healthcare. According to Elwyn et al. (29) model, 
there are three main steps for shared-decision making: introducing 
choice (choice talk), describing options (option talk) and helping 
patients explore preferences and make decisions (decision talk). 
This process is called ‘deliberation’ and allows patients to become 
aware of choices available, understand their options and have the 
time and support to consider what matters most to them. This may 
require more than one clinical contact not necessarily face-to-face 
and may include the use of decision support and discussions with 
others (29). According to this framework, the results presented 
here suggest a number of areas for practitioners’ improvement 
in the shared-decision making process. While generally themes 
emerging from GP advice show that practitioners considered 
patients’ issues with medications, offered alternative treatment 
choices and acted to modify treatment, this was not always the 
case (see Figures 2 and 3). The lack of being offered options about 
treatment or education about medications side effects, ended up 
in patients stopping secondary prevention medicines or in an on-
off adherence. Patients might benefit of more practitioners’ time 
and the use of decision support tools to understand their options 
and might need multiple treatment modifications (>2) to address 
side effects, in particular for statins. Advising patients to contact 
the practitioner if issues do occur even after multiple treatment 
adjustments is advisable. More attention could perhaps be paid to 
eliciting and listening to patients’ anxiety about stroke recurrence 
and providing reassurance that patients are on the recommended 
treatment.
Following up patients (even just by telephone) after any change 
in treatment or after advice on persisting with secondary prevention 
medications could ensure issues have resolved. Although deliberation 
may, in part, be done outside the clinical encounter, often patients 
wish to consolidate their views with a trusted clinician (29). A good 
relationship with a trusted clinician through shared decision-making 
may also make the patient feel confident enough to keep sharing 
problems with medication side effects or non-adherence. There is a 
time window when patients experience issues with secondary pre-
vention medications when practitioners’ intervention may improve 
persistence.
Patients often want to discuss options with others. Rapley has 
referred to this need to talk to others, at different times and places, 
as a ‘distributed’ deliberation process. Recognizing this need, and 
allowing time for it, is a cornerstone for effective shared decision 
making (30). In this study, feedback received by other forum par-
ticipants facilitated this distributed deliberation process and shared 
decision making. Forum participants’ feedback did not include 
incorrect or misleading statements, but rather provided peer sup-
port and underlined the central role of practitioners in managing 
secondary prevention medications. This hints that this online patient 
community was successful and raises questions as to whether online 
peer support may itself be effective in improving outcomes after 
stroke.
Considering the ease, low-cost and advantages of obtain-
ing patients’ information from online fora, more attention could 
be paid into studying health related issues using data from online 
communities.
Conclusions
While confirming previous research, this study of peer-to-peer online 
conversations offers a novel window to explore problems patients 
and carers encounter with secondary prevention medications and 
how these might affect their adherence. Side effects of medications, 
in particular statins may cause anxiety and resentment in some 
patients, and their concerns are not always addressed by practition-
ers. Interestingly, feedback from peers online was appropriate and 
supportive of the practitioners’ advice received.
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